Research status of tyrosine kinase inhibitors discontinuation in patients with chronic myelogenous leukemia / 肿瘤研究与临床

ABSTRACT

The clinical applications of tyrosine kinase inhibitors (TKI) greatly prolong the survival of patients with chronic myelogenous leukemia (CML). However, many problems such as drug side effects, drug resistance or intolerance and economic stress caused by long-term drug treatment have prevented a considerable number of patients from adhering to treatment. At present, a number of clinical trials have suggested that CML patients with stable deep molecular response can achieve treatment-free remission. This article reviews the current research status of discontinuation of TKI in patients with CML.